Clinicopathological significance of ERCC1 expression in breast cancer

Pathology Research and Practice

Volumn 209, Issue 6, 2013, Pages 331-336

  Gerhard, Renê ^b   Carvalho, Ana ^a   Carneiro, Vítor ^c   Bento, Rui San ^c   Uemura, Gilberto ^d   Gomes, Madalena ^b   Albergaria, André ^b   Schmitt, Fernando ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DO DIVINO ESPÍRITO SANTO   (Portugal)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Breast cancer; Breast cancer molecular subtypes; Excision repair cross complementation 1; Immunohistochemistry

Indexed keywords

ESTROGEN RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; ARTICLE; CARCINOMA; EXCISION REPAIR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CARCINOMA; CHI-SQUARE DISTRIBUTION; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84878386919     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.02.009     Document Type: Article

References (35)

1. Al-Haddad S., Zhang Z., Leygue E., et al. Psoriasin (S100A7) expression and invasive breast cancer. Am. J. Pathol. 1999, 155:2057-2066.
2. Badve S., Dabbs D.J., Schnitt S.J., et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011, 24:157-167.
3. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 2007, 18:522-528.
4. Britten R.A., Liu D., Tessier A., et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 2000, 89:453-457.
5. Chen X., Wu J., Lu H., et al. Measuring beta-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Sci. 2012, 103:262-268.
6. Colleoni M., Bagnardi V., Rotmensz N., et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res. Treat. 2009, 116:359-369.
7. Dufloth R.M., Matos I., Schmitt F., et al. Tissue microarrays for testing basal biomarkers in familial breast cancer cases. Sao Paulo Med. J. 2007, 125:226-230.
8. Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011, 22:1736-1747.
9. Goyal S., Parikh R.R., Green C., et al. Clinicopathologicalal significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76:679-684.
10. Handra-Luca A., Hernandez J., Mountzios G., et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin. Cancer Res. 2007, 13:3855-3859.
11. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J. Clin. Invest. 2011, 121:3797-3803.
12. Hudis C.A., Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl. 1):1-11.
13. Hwang I.G., Ahn M.J., Park B.B., et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008, 113:1379-1386.
14. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
15. Kim D., Jung W., Koo J.S. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J. Korean Med. Sci. 2011, 26:352-359.
16. Kim K.H., Do I.G., Kim H.S., et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 2010, 118:941-948.
17. Kim S.H., Kwon H.C., Oh S.Y., et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am. J. Clin. Oncol. 2009, 32:38-43.
18. Kwon H.C., Roh M.S., Oh S.Y., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol. 2007, 18:504-509.
19. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008, 14:1291-1295.
20. Matos I., Dufloth R., Alvarenga M., et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005, 447:688-694.
21. Metro G., Zheng Z., Fabi A., et al. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 2009, 28:172-180.
22. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355:983-991.
23. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
24. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res. 2005, 11:6100-6102.
25. Ring A.E., Smith I.E., Ashley S., et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 2004, 91:2012-2017.
26. Shao Y.Y., Kuo K.T., Hu F.C., et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn. J. Clin. Oncol. 2010, 40:286-293.
27. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 2001, 19:4298-4304.
28. Sidoni A., Cartaginese F., Colozza M., et al. ERCC1 expression in triple negative breast carcinoma: the paradox revisited. Breast Cancer Res. Treat. 2008, 111:569-570.
29. Silver D.P., Richardson A.L., Eklund A.C., et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. 2010, 28:1145-1153.
30. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874.
31. Sousa B., Paredes J., Milanezi F., et al. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol. Histopathol. 2010, 25:963-974.
32. Vilmar A., Sorensen J.B. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 2009, 64:131-139.
33. Wang L., Wei J., Qian X., et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8.
34. Weigelt B., Horlings H.M., Kreike B., et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008, 216:141-150.
35. Welsh C., Day R., McGurk C., et al. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer 2004, 110:352-361.